• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 1
  • 1
  • Tagged with
  • 70
  • 5
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

IGFBP-2 : a mediator of metabolism-driven prostate cancer progression and a new therapeutic target

Biernacka, Kalina January 2014 (has links)
This PhD work focuses on the effect of elevated glucose levels on the response of prostate cancer cell lines to chemotherapy. Then secondly it concentrates on evaluating the potential for modulating the effect. Clinically relevant prostate cancer is more frequent in Westernised societies and increasingly men have co-morbidities associated with a Western lifestyle; primarily diabetes, characterised by hyperinsulinemia and hyperglycaemia. Insulin-like growth factors and their binding proteins are important mediators of the effects of nutrition on growth and play a key role in the development of prostate cancer. I found that high glucose reduced Docetaxel-induced apoptosis in DU145 and LNCaP cells and that this was mediated by up-regulation of IGFBP-2. Glucose increased IGFBP-2 via increasing the acetylation of histones associated with the IGFBP-2 gene promoter. Next I studied metformin, which is a widely used anti-diabetic drug. The effect of metformin on induction of cell death was much greater in normal glucose conditions but co-treatment with metformin negated the high glucose-mediated reduction in sensitivity to Docetaxel. LKB 1 is required for activation of AMPK in CaP cells but was not essential to mediate induction of cell death in the model. A possible alternative pathway via which metformin exerts its action is through down-regulation of IGFBP-2 in DU145 and LNCaP cells, independently of AMPK. This finding could have important implications in relation to therapeutic strategies in prostate cancer patients presenting with diabetes.
2

Assessment of the BORIS protein as a potential blood and tissue biomarker of prostate cancer

Cheema, Zubair Ahmad January 2014 (has links)
BORIS, a paralogue of the transcription factor CTCF, is a member of the cancer-testis antigen family. BORIS is normally present only in the testis, however, it is aberrantly expressed in various tumours and, as recently reported, in leukocytes from breast cancer patients. The main aim of this study was to investigate BORIS expression in tissues and leukocytes from prostate cancer patients, and to correlate BORlS levels with clinical and pathological variables. To achieve this, BORIS immunoexpression was evaluated in human prostate tissues, cancer and benign prostate hyperplasia (BPH), and also in leukocytes from patients diagnosed with prostate cancer and BPH, and healthy donors. The staining was quantified using the immunoreactive score (IRS). BORIS, whilst absent in BPH tissues, was observed at varying levels in all prostate tumours analyzed, with the mean IRS= 6.78±0.89. Increased levels of BORIS protein positively correlated with Gleason score, T -stage and Androgen Receptor (AR) protein levels in prostate tumours. BORIS localization in the nucleus plus cytoplasm was also associated with higher BORIS levels and Gleason score. BORIS was not detected in leukocytes from healthy donors and patients with BPH, whereas 89% leukocyte specimens from prostate cancer patients were BORIS positive; the IRS values ranged between 1 and 8, with the average IRS= 2.51 ± 0.18. Positive relationship was observed between BORIS IRS, tumour stage and Gleason score however these results were not statistic all y significant. Detection of BORIS in prostate tumours suggests potential applications of BORIS as a biomarker for prostate cancer diagnosis, as an immunotherapy target and, potentially, a prognostic marker of more aggressive prostate cancer. The association of BORIS with AR indicates BORIS involvement in the growth and development of prostate tumours. Although BORIS has been shown to have properties as a blood biomarker, further validation will be required due to the lack of statistical significance.
3

Measurement of response shift in quality of life and symptom assessment in patients with advanced prostate cancer and their partners

Rees, Jonathan January 2003 (has links)
No description available.
4

Studies on the mechanisms by which isoflavones protect against prostate cancer : focus on invasion/metastasis

Millar, Julie Grace January 2005 (has links)
No description available.
5

Men's experiences of testicular cancer and its treatment : a grounded theory study

Robinson, David S. January 2006 (has links)
No description available.
6

Proteomic profiling of prostate cancer epithelial cell plasma membrane proteins

Brinham, Claire Louise January 2007 (has links)
No description available.
7

Expression of splice variants of PKC zeta in the biology of prostate cancer

Ireland, Samantha Jayne January 2006 (has links)
No description available.
8

Development and study of whole cell vaccines in a novel mouse prostate model

Labarthe, Marie-Christine January 2004 (has links)
No description available.
9

An investigation into the genetic basis of testicular germ cell tumours

Adamah, David Jackson Bukari January 2003 (has links)
No description available.
10

Characterisation of androgen receptor-interacting proteins in prostate cancer

Whitaker, Hayley Caroline January 2003 (has links)
No description available.

Page generated in 0.04 seconds